Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04390724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimizing Y90 Therapy for Radiation Lobectomy

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 31, 2026 → Nov 27, 2026
See other at-risk trials from Northwestern University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Nov 27, 2026
    • Eligibility criteria expanded, about 27 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Primary and study completion pushed from Jul 2026 to Jul 31, 2026
    • Site details revised at 2 of 2 sites
    v10
  3. Study sites: 1 to 2v9
  4. Primary completion date: Jun 2025 to Jul 2026
    • Study completion date: Jun 2026 to Jul 2026
    v8
  5. Study completion date: Jun 2025 to Jun 2026
    • Interventions: Y90 radioembolization (Other) to Y90 radioembolization (Device)
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. 3 versions Re-verified since Aug 27, 2021, no change to tracked fieldsv4-v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 30, 2020 to Jul 17, 2020
    • Site details revised
    v3
  3. Start date: Jun 2020 to Jul 30, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Trial Details
NCT Number NCT04390724
Lead Sponsor Northwestern University
Collaborators: Mayo Clinic
Conditions
(from sponsor)		 HCC, Resection, Transplant, Metastatic Cancer, Adult Primary Liver Cancer
Related terms Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov